LGVN News and Press, Longeveron Inc. From 10/06/23

2023-10-06 08:53:38 ET OMNIQ ( OMQS ) -44% announces pricing of public offering. Wheeler Real Estate Investment Trust  ( WHLR ) -21% . ShiftPixy  ( PIXY ) -19% . Nanobiotix  ( NBTX ) -15% . Aehr Test ( AEHR ) -11% . ...

2023-10-05 10:36:06 ET More on Longeveron Longeveron: Alzheimer's Phase 2 Data Around The Corner Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript Longeveron announces pricing for rights offering Seeking Alpha’s Quant Rating on Longeveron ...

2023-10-05 10:00:20 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Citi turns cautious on pharmaceuticals and biotech For further details see: Orchard Therapeutics, Longeveron among healthcare movers

2023-10-05 09:35:24 ET DENVER, Colo., Oct 5, 2023 ( www.247marketnews.com)- Longeveron Inc. (NASDAQ: LGVN) reported, this morning, positive top-line results from its Lomecel-B, its investigational product, Phase 2a trial for the treatment of mild Alzheimer’s disease. The Company ...

Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET Primary Endpoint of Safety Met Across all Study Groups Statistical Significance Met for Secondary Endpoint Composite Alzheimer’s Disease Score (CADS) for Lomecel-B™ Low-Dose and for t...

Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product Longeveron’...

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the...

Longeveron management will present at the 25th Annual H.C. Wainwright Global Investment Conference scheduled for September 11-13, 2023, in New York Wa’el Hashad, the company’s CEO, will discuss Longeveron’s cellular therapy programs in a pre-recorded presentation. Both he a...

(NewsDirect) By David Willey, Benzinga Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates , plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions conti...

Longeveron (NASDAQ: LGVN; LGVNR) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has issued a lett...